Systems Biology Analyses Show Hyperactivation of Transforming Growth Factor-β and JNK Signaling Pathways in Esophageal Cancer
Authors:
- 1 May 2019
- journal article
- research article
- Published by Elsevier in Gastroenterology
- Vol. 156 (6) , 1761-1774
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- The Genomic Landscapes of Human Breast and Colorectal CancersScience, 2007
- Reversible Smad-Dependent Signaling between Tumor Suppression and OncogenesisCancer Research, 2007
- Selective Loss of TGFβ Smad-Dependent Signalling Prevents Cell Cycle Arrest and Promotes Invasion in Oesophageal Adenocarcinoma Cell LinesPLOS ONE, 2007
- Leptin Stimulates Proliferation and Inhibits Apoptosis in Barrett’s Esophageal Adenocarcinoma Cells by Cyclooxygenase-2-Dependent, Prostaglandin-E2-Mediated Transactivation of the Epidermal Growth Factor Receptor and c-Jun NH2-Terminal Kinase ActivationEndocrinology, 2006
- Impaired transforming growth factor β signalling in Barrett’s carcinogenesis due to frequent SMAD4 inactivationGut, 2005
- Inhibition of Tumor Growth, Angiogenesis, and Tumor Cell Proliferation by a Small Molecule Inhibitor of c-Jun N-terminal KinaseThe Journal of Pharmacology and Experimental Therapeutics, 2005
- GENETIC AND EPIGENETIC ALTERATIONS IN COLON CANCERAnnual Review of Genomics and Human Genetics, 2002
- SB-431542 Is a Potent and Specific Inhibitor of Transforming Growth Factor-β Superfamily Type I Activin Receptor-Like Kinase (ALK) Receptors ALK4, ALK5, and ALK7Molecular Pharmacology, 2002
- Identification of Novel Inhibitors of the Transforming Growth Factor β1 (TGF-β1) Type 1 Receptor (ALK5)Journal of Medicinal Chemistry, 2002
- SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinaseProceedings of the National Academy of Sciences, 2001